Global Medical REIT Inc. (NYSE:XRN – Get Free Report) CEO Mark Okey Decker, Jr. acquired 6,875 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The shares were purchased at an average cost of $35.92 per share, for a total transaction of $246,950.00. Following the acquisition, the chief executive officer owned 75,199 shares in the company, valued at $2,701,148.08. This represents a 10.06% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Global Medical REIT Price Performance
XRN stock traded up $0.25 during midday trading on Thursday, reaching $36.52. 100,235 shares of the stock were exchanged, compared to its average volume of 89,274. Global Medical REIT Inc. has a 52 week low of $29.05 and a 52 week high of $39.93. The company has a fifty day moving average price of $36.59 and a 200 day moving average price of $35.80. The company has a debt-to-equity ratio of 1.68, a current ratio of 0.68 and a quick ratio of 0.68. The stock has a market capitalization of $483.50 million, a PE ratio of 9.82 and a beta of 1.09.
Global Medical REIT (NYSE:XRN – Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $4.78 EPS for the quarter, beating analysts’ consensus estimates of $0.83 by $3.95. Global Medical REIT had a return on equity of 13.74% and a net margin of 36.82%.The firm had revenue of $39.75 million for the quarter. As a group, analysts expect that Global Medical REIT Inc. will post 3.06 EPS for the current fiscal year.
Institutional Inflows and Outflows
Wall Street Analyst Weigh In
XRN has been the subject of a number of recent analyst reports. Compass Point reissued a “neutral” rating and set a $38.00 target price (down from $50.00) on shares of Global Medical REIT in a research report on Thursday, May 7th. Zacks Research raised shares of Global Medical REIT to a “hold” rating in a research note on Wednesday, July 22nd. Raymond James Financial began coverage on shares of Global Medical REIT in a research report on Wednesday, June 17th. They set a “market perform” rating for the company. BMO Capital Markets lifted their target price on shares of Global Medical REIT from $39.00 to $40.00 and gave the stock a “market perform” rating in a research note on Monday, July 13th. Finally, Weiss Ratings lowered shares of Global Medical REIT from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, July 30th. Two analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Global Medical REIT has an average rating of “Hold” and a consensus target price of $40.25.
View Our Latest Research Report on Global Medical REIT
Key Headlines Impacting Global Medical REIT
Here are the key news stories impacting Global Medical REIT this week:
- Positive Sentiment: Director Charles Fitzgerald purchased 14,000 shares for approximately $500,920 at an average price of $35.78, increasing his direct ownership by 11.21%. This followed his purchase of another 27,600 shares, worth about $991,944, on August 10. SEC insider purchase filing
- Positive Sentiment: CEO Mark Okey Decker Jr. bought 8,000 shares for $287,040 on August 10 and an additional 550 shares for $19,800 on August 11. The purchases increased his holdings by 13.38% and 0.81%, respectively, signaling management confidence in the company’s valuation and outlook. CEO insider buying report
- Positive Sentiment: Global Medical REIT reported quarterly earnings per share of $4.78, exceeding the $0.83 consensus estimate by $3.95, with revenue of $39.75 million. The company posted a 36.82% net margin and 13.74% return on equity, while analysts expect full-year EPS of $3.06.
- Positive Sentiment: Some analysts remain constructive: Citizens JMP raised its price target to $42 from $40 and maintained an outperform rating. The average analyst price target is $40.25, above the recent trading level.
- Neutral Sentiment: Institutional ownership remains substantial at 57.52%. Invesco increased its position, and several other investment firms recently initiated or expanded holdings, providing some support from professional investors.
- Negative Sentiment: Analyst sentiment is mixed, with an overall “Hold” rating. Compass Point cut its price target to $38 from $50, Wall Street Zen downgraded the stock to “Sell,” and Raymond James initiated coverage at “Market Perform.”
- Negative Sentiment: The REIT carries meaningful leverage, with a debt-to-equity ratio of 1.68 and current and quick ratios of 0.68, factors that could limit financial flexibility if interest rates or property-market conditions worsen.
Global Medical REIT Company Profile
Global Medical REIT (NYSE: GMRE) is a real estate investment trust focused on owning and managing healthcare-related properties across the United States. The company acquires, develops and leases a diversified portfolio of medical office buildings, outpatient facilities, long-term care centers and other specialized healthcare real estate. By concentrating on essential healthcare assets, Global Medical REIT seeks to generate stable, long-term rental income under triple-net and modified gross lease structures.
Since its incorporation in 2016 and initial public offering in 2017, the company has pursued an acquisitive growth strategy targeting markets with strong demographic trends and limited supply of modern medical facilities.
Featured Articles
- Five stocks we like better than Global Medical REIT
- Asian Market Circuit Breakers Hit Stocks, Not AI Demand
- Riot Platforms Re-Wires the Ledger for a $9B AI Power Play
- Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?
- Joby’s Defense Pivot Accelerates With $500M Resonant Sciences Deal
Receive News & Ratings for Global Medical REIT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Medical REIT and related companies with MarketBeat.com's FREE daily email newsletter.
